Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
Clin Infect Dis
.
2022 Aug 24;75(1):178-179.
doi: 10.1093/cid/ciab1000.
Authors
Louise Caldwell
1
,
Anjaneya Bapat
2
3
,
Lydia N Drumright
4
,
Jonathan Lambourne
2
,
Fergus G Jimenez-England
2
,
James Aries
1
,
Lydia Eccersley
1
,
Simon Hallam
1
,
Silvia Montoto
1
,
Heather Oakervee
1
,
John Riches
1
,
Samir G Agrawal
1
2
Affiliations
1
Department of Haemato-Oncology, St Bartholomew's Hospital, London, United Kingdom.
2
Department of Infectious Diseases & Microbiology, St Bartholomew's Hospital, London, United Kingdom.
3
Blizard Institute, Queen Mary University of London, London, United Kingdomand.
4
University of Washington, School of Medicine, Division of Allergy and Infectious Diseases, Harborview Medical Center, Seattle, Washington, USA.
PMID:
34864924
PMCID:
PMC9402662
DOI:
10.1093/cid/ciab1000
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibiotic Prophylaxis
Ciprofloxacin* / therapeutic use
Humans
Neoplasms* / complications
Neoplasms* / drug therapy
Substances
Ciprofloxacin